Therefore, in cancers that maintain HER2 overexpression after T-DM1 resistance similar to that in the BT-474bTDR cells, signal inhibitors such as TRAS and PER, other than antibody–drug conjugates, might be a reasonable treatment. The gene discussed is ERBB2; the disease is cancer.